Tuesday, Masimo Corp. (MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced the Food and Drug Administration or FDA clearance of its latest innovation, Masimo Rainbow SET Acoustic Monitoring providing noninvasive and continuous respiration rate or RRa that is accurate, easy-to-use, and enhances patient compliance.
Masimo Rainbow SET Acoustic Monitoring may enable earlier detection of respiratory compromise and patient distress, offering a breakthrough in patient safety for post-surgical patients on the general floor, the company said.
Masimo Founder and Chief Executive Officer, Joe Kiani, said, "Solving 'unsolvable' problems that have plagued patient monitoring is key to advancing medicine and improving patient care. Masimo Rainbow SET Acoustic Monitoring addresses a longstanding and growing need to accurately and easily monitor patient breathing, which is expected to improve patient safety and decrease the cost of care in hospitals. It also adds another compelling reason for hospitals to choose the Masimo Rainbow SET upgradeable platform for pulse oximetry, Pulse CO-Oximetry, and now -- Acoustic Monitoring."
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.